21Indexed trials
mesh condition
Tuberous Sclerosis
Intelligence
Tuberous Sclerosis intelligence: 21 indexed trials, 5 recruiting studies, 17 sponsors across 23 countries.
5Recruiting
17Sponsors
23Countries
Leading sponsors
NYU Langone Health20 recruiting
Jazz Pharmaceuticals21 recruiting
Marinus Pharmaceuticals20 recruiting
Novartis Pharmaceuticals21 recruiting
GRIN Therapeutics, Inc.11 recruiting
Martina Bebin10 recruiting
Mustafa Sahin10 recruiting
Neurim Pharmaceuticals Ltd.10 recruiting
Noema Pharma AG10 recruiting
Peking Union Medical College Hospital10 recruiting
Rush University Medical Center11 recruiting
UK Kidney Association11 recruiting
Geographic activity
United States14trials
United Kingdom7trials
Italy6trials
Poland5trials
Canada5trials
Spain5trials
Netherlands4trials
China4trials
Australia3trials
France3trials
Israel2trials
Japan2trials
Leading interventions
Everolimus2trials
Ganaxolone2trials
Basimglurant with crossover to Placebo1trials
Cannabidiol Oral Solution [Epidiolex]1trials
Circadin 10 mg1trials
Circadin 2 mg1trials
Delayed Vigabatrin (Placebo)1trials
Early Vigabatrin1trials
Epidiolex 100 mg/mL Oral Solution1trials
Everolimus (RAD001)1trials
Everolimus Placebo1trials
Functional Behavioral Training (FBT)1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.